Neurocrine Biosciences Director Gorman Buys, Sells 106,322 Shares on 8/7/2025

Neurocrine Biosciences Inc. [NBIX] has reported a recent transaction involving Director Gorman Kevin Charles. On August 7, 2025, Charles purchased 106,322 shares at a price of $35.99 per share. However, he subsequently sold the same number of shares at a price of $126.41 per share on the same day.

Neurocrine Biosciences Inc. (NBIX) recently reported a significant transaction involving Director Kevin Charles Gorman. On August 7, 2025, Gorman exercised 106,322 non-qualified stock options at an exercise price of $35.99 per share, and subsequently sold the same number of shares at a weighted-average price of $126.4111 per share on the same day [1]. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 24, 2025 [2].

The sale was conducted by a broker and occurred within the range of $124.80 to $129.03 per share. Following the transaction, Gorman's beneficial ownership decreased from 620,918 shares to 514,596 shares. The options were granted on February 5, 2016, and were due to expire on February 5, 2026 [2].

The use of a 10b5-1 plan and the issuer's non-amendable policy indicate that the transactions were pre-planned and compliant with corporate governance regulations. This transparent disclosure of the plan and price range is a positive signal for investors monitoring insider selling practices [2].

References:
[1] https://www.tradingview.com/news/tradingview:7f18f2aa7471c:0-neurocrine-biosciences-director-sells-over-13-million-in-company-stock/
[2] https://www.stocktitan.net/sec-filings/NBIX/form-4-neurocrine-biosciences-inc-insider-trading-activity-22b9080c90f4.html